David Ridley
Senior Editor – Europe
During his time at OTC bulletin, David focused mainly on the European OTC market, especially German-speaking countries: Germany, Austria and Switzerland). David is interested in European OTC, herbal/homeopathic, food supplement and self-care medical device regulation, and prescription-to-OTC switches in particular. Before working for OTC bulletin, David was a Lecturer in English and Journalism, and alongside his job David moonlights as a musician in a heavy metal band.
Remove Alert
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From David Ridley
Switzerland Provides Gateway Into Mainland Europe For BASF’s Hepacor
With the Swiss launch of its Non-Alcoholic Fatty Liver Disease supplement, BASF is looking to make inroads into continental Europe.
Majority Of Spanish OTC Firms Investing Heavily In Digital
A recent ANEFP survey shows that the majority of Spanish OTC firms consider their digital strategies to be "very advanced."
Novartis Seeks 'Amicable' Resolution Of German Probiotics Dispute
Novartis is in discussion via its Hexal subsidiary with Germany's Association for Social Competition (VSW) over whether it must withdraw its Biosan range of probiotic supplements currently on the German market following a recent Higher Regional Court ruling.
UK Women’s Health Professionals Join Growing Movement For OTC Oral Contraceptives
The UK's Royal College of Obstetricians and Gynaecologists joins a steadily loudening chorus of organizations calling for the prescription-to-OTC switch of oral contraceptives.
Self-Care Medical Devices One Step Closer To Four-Year MDR Extension
Members of the European Parliament will soon decide whether to grant self-care medical devices such as nasal sprays and throat lozenges the same four-year extension as high-risk devices under the new EU Medical Devices Regulation implementation rules.
Prescription-To-OTC Switch Of Daily Contraceptives And High-Dose Statins In The UK?
Daily contraceptives and high-dose statins are two OTC categories that have future switch potential, according to UK self-care industry association CEO John Smith.